Overview
Employees
51-200
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 11, 2021 | Visus Therapeutics Raises $20M in Funding | Visus Therapeutics, Inc., a Seattle, WA- and and Orange County, Calif.,-based based clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, raised $20m in fu... |
| Aug 10, 2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced the closing of $20 million in preferred stock financing, l... |
| Aug 10, 2021 | Visus raises $20M ahead of data drop on rival to AbbVie prospect | Visus Therapeutics has raised a further $20 million as it closes in on the release of midphase data on a potential treatment for age-related long-sightedness. The financing comes on the heels of phase 3 data on rival candidates in developme... |
| Aug 10, 2021 | Visus raises $20M ahead of data drop on rival to AbbVie prospect Age-Appropriate Formulation Development for Pediatric Trials-Challenges and Considerations | Visus Therapeutics has raised a further $20 million as it closes in on the release of midphase data on a potential treatment for age-related long-sightedness. The financing comes on the heels of phase 3 data on rival candidates in developme... |
| Aug 10, 2021 | Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners | All the sessions from Transform 2021 are available on-demand now. Watch now. Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activiti... |
| Mar 10, 2021 | Visus Therapeutics raises $36M from J&J’s VC arm, others to develop eye drop that treats presbyopia | Visus Therapeutics, a Seattle-based startup developing a presbyopia-correcting eye drop, raised $36 million. Johnson & Johnson Innovation, the venture capital arm of J&J, invested in the Series A round, in addition to RTW Investment... |
| Mar 9, 2021 | Visus Therapeutics Raises $36M in Series A Financing | Visus Therapeutics Inc., a Seattle, WA- Orange County, Calif.-based based clinical-stage pharmaceutical company developing a presbyopia-correcting eye drop, closed a $36m Series A financing. Backers included Johnson & Johnson Innovation... |
Reviews 0
FAQ about ViSUS
What has the press written about ViSUS?
Parsers VC has collected 8 articles mentioning ViSUS, among them “Visus Therapeutics Raises $20M in Funding” (Aug 11, 2021) and “Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners” (Aug 10, 2021).
Is ViSUS still active?
ViSUS is probably closed: its latest activity on Parsers VC dates from Aug 12, 2021.